Current Choices and Management of Treatment in Persons with Severe Hemophilia A without Inhibitors: A Mini-Delphi Consensus

Autor: Antonio Coppola, Massimo Franchini, Giovanni Pappagallo, Alessandra Borchiellini, Raimondo De Cristofaro, Angelo Claudio Molinari, Rita Carlotta Santoro, Cristina Santoro, Annarita Tagliaferri

Publikováno v: Journal of Clinical Medicine; Volume 11; Issue 3; Pages: 801
Journal of Clinical Medicine, Vol 11, Iss 801, p 801 (2022)

Background. Regular treatment to prevent bleeding and consequent joint deterioration (prophylaxis) is the standard of care for persons with severe hemophilia A, traditionally based on intravenous infusions of the deficient clotting FVIII concentrates

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef23804bc2de4e1fe4e55ef479ba03ac

Willingness to pay for eliminating the risk of being infected by blood-borne diseases in regular replacement treatment for patients with haemophilia

Autor: Sara Olofsson, Katarina Steen Carlsson, Erik Berntorp, Emmelie Persson, Flemming Axelsen, Ulf Persson

Publikováno v: Nordic Journal of Health Economics, Vol 4, Iss 2 (2016)

Hemophilia is a set of lifelong bleeding disorders linked to the X chromosome. Standard treatment for patients with severe hemophilia is intensive replacement therapy with intravenous injection of coagulation factor concentrates to prevent spontaneou

Externí odkaz: https://doaj.org/article/3f1caeb3bd544f30bf93e876caef5cd8

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Inhibitor incidence after intensive FVIII replacement for surgery in mild and moderate haemophilia A: a prospective national study in the Netherlands

Autor: Evelien P. Mauser-Bunschoten, Frank W.G. Leebeek, Felix J. M. van der Meer, Marjolein Peters, Corien L. Eckhardt, Karin Fijnvandraat

Publikováno v: British Journal of Haematology, 157(6), 747-752. Wiley-Blackwell Publishing Ltd
British journal of haematology, 157(6), 747-752. Wiley-Blackwell
British Journal of Haematology, 157(6), 747-752

Inhibitor development is currently the most severe complication in mild/moderate haemophilia A patients, causing increased bleeding tendency, hospitalization and mortality. It has been suggested that receiving high doses of factor VIII (FVIII) concen

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0cdd9e442db9ada9bebff806ecf25bf
https://pure.eur.nl/en/publications/e522d6a1-ea38-45cd-9ff7-0e45f7190e79

Lymphocyte subset abnormalities in multitransfused HIV-negative haemophilia A patients are not due to chronic hepatitis C virus infection

Autor: Meijer, K, van der Meer, J, Smit, JW, Verspiek, SPJ, Haagsma, EB, Smid, WM

Publikováno v: British Journal of Haematology, 109(3), 529-533. Wiley

Several abnormalities of immune parameters have been described in HIV-negative haemophiliacs, including changes in numbers of T4 and T8 cells, T4/T8 ratio and numbers of activated T cells, To assess the contribution of hepatitis C to these abnormalit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=narcis______::3b720906f9daf183567f9ed23a1f6192
https://research.rug.nl/en/publications/556bc69e-fc9b-4c61-8078-589bf9103e13